Perrigo Closes Acquisition of Generic Retin-A Portfolio from Matawan.

MANews-(C)2009-2016

26 January 2016 - Irish drugmaker Perrigo Co plc (NYSE: PRGO) (TASE: PRGO) has completed the acquisition of a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, LLC, the company said.

Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated.

Generic and brand sales of Retin-A, which is indicated for the topical treatment of acne vulgaris, were approximately USD 290m for the 12 months ending November 2015.

The transaction is expected to immediately exceed Perrigo's ROIC threshold and add more than USD 0.20 in adjusted EPS within the first 12 months post-close after the exclusion of estimates for intangible amortization, transaction costs and integration related expenses.

Perrigo is an over-the-counter consumer goods and leading specialty pharmaceutical company, offering patients and customers high quality products at affordable prices.

The company is also a provider of generic extended topical prescription products, and it receives royalties from sales of the multiple sclerosis drug Tysabri.

Country: USA

Sector: Pharmaceuticals

Target: Portfolio of generic dosage forms and strengths of Retin-A

Buyer: Perrigo Co plc

Vendor: Matawan Pharmaceuticals

Deal size in USD:

Type: Corporate Acquisition

Financing: Cash and Stock

Status: Closed

Buyer advisor: , ,

Comment: Terms of the deal were not disclosed